Zacks Investment Research lowered shares of Millendo Therapeutics (NASDAQ:MLND) from a hold rating to a sell rating in a research report released on Wednesday, Zacks.com reports.

According to Zacks, “Millendo Therapeutics Inc. is a biopharmaceutical company. It focuses on developing novel treatments for orphan endocrine diseases. The company’s product candidate consists of AZP-531 and ATR-101 which are in clinical stage. Millendo Therapeutics Inc., formerly known as OvaScience Inc., is based in Ann Arbor, United States. “

MLND has been the subject of a number of other research reports. Jefferies Financial Group initiated coverage on shares of Millendo Therapeutics in a research report on Wednesday, March 13th. They set a buy rating and a $22.00 target price for the company. ValuEngine lowered shares of Welbilt from a hold rating to a sell rating in a research report on Wednesday, June 12th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $23.25.

NASDAQ:MLND traded down $0.74 during trading hours on Wednesday, reaching $11.08. The company’s stock had a trading volume of 72,100 shares, compared to its average volume of 39,002. The company has a market cap of $167.99 million, a P/E ratio of -0.63 and a beta of 2.62. Millendo Therapeutics has a one year low of $6.77 and a one year high of $17.34. The business has a 50-day moving average of $13.47. The company has a current ratio of 7.83, a quick ratio of 7.83 and a debt-to-equity ratio of 0.02.

Millendo Therapeutics (NASDAQ:MLND) last released its earnings results on Wednesday, May 15th. The company reported ($0.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.08). Sell-side analysts forecast that Millendo Therapeutics will post -3.25 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in MLND. Great Point Partners LLC acquired a new position in shares of Millendo Therapeutics during the fourth quarter valued at about $10,240,000. Worth Venture Partners LLC acquired a new position in shares of Millendo Therapeutics during the fourth quarter valued at about $206,000. BlackRock Inc. acquired a new position in shares of Millendo Therapeutics during the fourth quarter valued at about $203,000. Tibra Equities Europe Ltd acquired a new position in shares of Millendo Therapeutics during the first quarter valued at about $303,000. Finally, Geode Capital Management LLC acquired a new position in shares of Millendo Therapeutics during the fourth quarter valued at about $113,000. 44.07% of the stock is owned by institutional investors and hedge funds.

Millendo Therapeutics Company Profile

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Featured Article: Should You Consider an Index Fund?

Get a free copy of the Zacks research report on Millendo Therapeutics (MLND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.